Please assess the completion status of the following clinical trial:

Trial Title: 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~DISEASE CHARACTERISTICS:~* Histologically confirmed AL amyloidosis~  * Persistent or recurrent disease after 1 course of prior high-dose chemotherapy~* Previously treated with autologous stem cell transplantation~* Significant initial improvement in organ function after prior high-dose melphalan, defined by at least 1 of the following:~  * Complete hematologic remission (e.g., absence of monoclonal spike by immunofixation in serum and urine AND less then 5% plasma cells in bone marrow with no clonal predominance) OR partial hematologic response (e.g., any decrease in serum or urine monoclonal protein OR decrease in bone marrow plasmacytosis)~ * Greater than 50% reduction in proteinuria with preservation of creatinine clearance~ * Greater than 50% reduction in alkaline phosphatase OR at least 2 cm decrease in liver size by physical exam~ * Subjective neurologic improvement, as confirmed by neurologist~ * Cardiac stabilization of disease confirmed by echocardiography defined as less than 2 mm increase in mean wall thickness and/or less than 20 g increase in left ventricular mass~ * Improvement in performance status\* NOTE: \*This criteria alone does not constitute significant improvement in organ function~* Prior stem cell yield must have been ≥ 2 x 10\^6 CD34+ cells/kg~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~Chemotherapy~* See Disease Characteristics~* No chemotherapy after first transplantation~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~PATIENT CHARACTERISTICS:~Age~* 18 to 65~Performance status~* Southwest Oncology Group- 0-2~Life expectancy~* More than 6 months~Hematopoietic~* See Disease Characteristics~Hepatic~* See Disease Characteristics~Renal~* See Disease Characteristics~Cardiovascular~* See Disease Characteristics~* Left ventricular ejection fraction ≥ 45% by multiple gated acquisition scan or echocardiogram~Pulmonary~* diffusing capacity of lung for carbon monoxide ≥ 50%~Exclusion Criteria:~* No myelodysplastic syndromes~* No abnormal bone marrow cytogenetics~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* Acceptable toxicity from first transplantation, confirmed by the transplant team~* HIV negative~* No other concurrent malignancy except treated skin cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 2nd Stem Cell Transplant (Type: EXPERIMENTAL): Mobilization with filgrastim autologous stem cell transplantation with melphalan conditioning stem cell infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).